Vmbook Online ordering
Enzymotec Ltd
Enzymotec Ltd. is a biotechnology company that focuses on developing, manufacturing, and marketing bio-active lipid-based products. The company provides nutritional solutions and medical foods/dietary supplements. It offers INFAT, a fat emulsion product; formula for infant nutrition; and supplements for foetal life. The company was once known as AMARANTIN Holding corp. and changed its name to Enzymotec Ltd. in June 2013. Enzymotec Ltd. was founded in 1988 and is headquartered in Migdal Ha'Emek, Israel.
Fundamentals
* Name: Enzymotec Ltd.
* Ticker: ENZY
* Exchange: OTCMKTS
* Industry: Biotechnology
* Sector: Healthcare
* Founded: 1988
* Headquarters: Migdal Ha'Emek, Israel
* Employees: 42
* Revenue: 34.16M
* EBITDA: 4.51M
* Net income: -10.88M
* Debt: 26.46M
Financial Highlights
* Revenue has been steadily increasing over the past few years, with a 5-year annual revenue growth rate of 14.30%.
* Enzymotec's stock price has been volatile in recent months, however, the company's financials are stable.
* The company has a strong balance sheet with low debt and high cash reserves.
* The company's margins have been increasing steadily over the past few years.
* The company's return on equity has been positive in recent years, indicating that the company is profitable.
Growth and Earnings
* Revenue Growth (5-year CAGR): 14.30%
* Net Income Growth (5-year CAGR): -24.70%
* Earnings Per Share (EPS) Growth: -28.10%
* The company's stock price has been volatile in recent months, however, the company's financials are stable.
Downsides
* The company's future profitability is uncertain, as its net income has been negative in the last year.
* The company has a high level of debt compared to its equity.
* The company's return on equity has been negative in recent years, indicating that the company is not profitable.
Upsides
* The company's revenue has been steadily increasing over the past few years.
* The company has a strong balance sheet with low debt and high cash reserves.
* The company's margins have been increasing steadily over the past few years.